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ABSTRACT 
A series of 5,7-dibromoisatin semicarbazones have been synthesized in good yield, involving 
aryl urea and aryl semicarbazide formation. The structures of the synthesized compounds 
were confirmed on the basis of their spectral data. All the compounds were evaluated for anti-
convulsant and CNS depressant activities. Anticonvulsant activity was determined after intra-
peritoneal (i.p.) administration to mice by maximal electroshock (MES) induced seizure 
method and minimal motor impairment was determined by rotarod test. A computational 
study was carried out for prediction of pharmacokinetic properties and making them potential-
ly promising agents for the treatment of epilepsy. Compounds (Z)-1-(5,7-dibromo-2-oxo-
indolin-3-ylidene)-4-(4-chlorophenyl)semicarbazide (DH-05), (Z)-1-(5,7-dibromo-2-oxoindo-
lin-3-ylidene)-4-(3-chloro-4-fluorophenyl)semicarbazide (DH-11) and (Z)-1-(5,7-dibromo-1-
methyl-2-oxoindolin-3-ylidene)-4-(3-chloro-4-fluorophenyl)semicarbazide (DH-12) exhibited 
prominent anticonvulsant effect in the series with little or no neurotoxicity and little CNS de-
pressant effect as compared to standard drug. 
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INTRODUCTION 
Epilepsy is a disease of complex nature 
and of different etiology with huge patient 
load of varying age groups involving both 
sexes (Verma et al., 2004). On an average, 
0.25 million new cases of epilepsy are re-
ported every year. Mainly two kinds of epi-
lepsy, namely grand mal and petit mal are 
prevalent (Siddiqui et al., 2007). Available 
drugs are effective in only 60 – 80 % of 
epileptic patients.  
During the past decade, several new 
drugs have been approved to be used as an-
tiepileptic drugs (Rufinamide, Retigabine, 
Pregabaline, Remacemide, etc.) (Yogees-
wari et al., 2005). Despite the optimal use 
of available antiepileptic drugs (AEDs), 
many patients fail to experience seizure 
control and others do so only at the expense 
of significant toxic effects. It is estimated 
that available medication controls seizures 
in only 50 % of patients or decrease inci-
dence in only 75 % of patients (Agarwal et 
al., 2004). Anticonvulsant drugs, showing 
activity with MES (maximal electroshock) 
test are generally useful in grand mal (Ver-
ma et al., 2004).  
Literature survey showed that isatin 
molecule has positive anticonvulsant effects 
during its initial screening in the MES test 
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(Pandeya et al., 2002; Julian et al., 1952; 
Popp 1984; Jursic et al., 2002; Hewawasam 
et al., 2002). Substitution of hydrogen 
(from –NH in indole nucleus) with methyl 
group enhanced the lipophilicity of the 
compounds (Smitha et al., 2008). In recent 
times, semicarbazones are emerging as 
novel anticonvulsant drugs. More than 300 
compounds have been prepared and tested 
in animal models. Representative semi-
carbazones, like 4-bromobenzaldehyde 
semicarbazone, have shown to have activity 
comparable with or even exceeding that of 
phenytoin (Dilantin) in the maximal elec-
troshock (MES)-induced seizure test in 
mice (Siddiqui et al., 2007). Aryl semi-
carbazones displaying anticonvulsant ac-
tivity in the MES screen interact at a specif-
ic binding site referred as the hydrogen 
bonding area and aryl binding site respec-
tively (Dimmock et al., 1995). Terminal 
amino group of aryl semicarbazones was 
shown to affect the binding properties at the 
hydrogen bonding area (Dimmock et al., 
1999; Pandeya et al., 1998). However, Pan-
deya et al. have suggested a new pharma-
cophore model for semicarbazones display-
ing anticonvulsant activity (Figure 1). They 
proposed that terminal amino function of 
semicarbazones could be substituted with a 
lipophilic substituted aryl ring (Jain et al., 
2010). Proposed pharmacophore model 
contains four binding sites for interaction 
with a macromolecular complex in vivo. 
1. An aryl hydrophobic binding site (A) 
with halogen substituent preferably at 
para position 
2. A hydrogen bonding domain (HBD) 
3. An electron donor group (D) 
4. Another hydrophobic-hydrophilic site 
controlling the pharmacokinetic proper-
ties of the anticonvulsant (C) 
These new aspects might be useful for 
designing prototypic molecules with poten-
tial anticonvulsant activity (Figure 2). 
These observations encouraged us to syn-
thesize a series of 5,7-dibromoisatin semi-
carbazones which were evaluated their anti-
convulsant and toxicological profiles. 
CHEMISTRY 
The synthesis of 5,7-dibromoisatin 
semicarbazones DH-01–DH-14 was 
achieved as depicted in Scheme 1. Substi-
tuted aniline was treated with sodium cya-
nate in the presence of glacial acetic acid 
according to the known urea preparation 
method, to yield aryl urea. Then aryl urea 
on condensation with hydrazine hydrate in 
ethanol in the presence of sodium hydrox-
ide gave the aryl semicarbazide. The 5,7-
dibromoisatin semicarbazones DH-01–DH-
14 were prepared by reaction of the appro-
priate 5,7-dibromoisatin or N-methyl 5,7-
dibromoisatin with aryl semicarbazide in 
presence of anhydrous sodium acetate. The 
synthesized products showed a single spot 
on TLC and had IR and 1H-NMR spectra in 
accordance with their anticipated structures. 
In general, IR spectra showed the C = N 
peak at 1610 – 1598 cm–1 and the NH 
stretching vibrations at 3424 – 3315 cm–1. 
The 1H-NMR spectrum revealed that the 
CO–NH proton at 12.19 – 11.25 and the ar-
yl NH proton that showed a singlet at 
9.99 – 9.72 were D2O exchangeable. The 
physical characterization data of the synthe-
sized compounds are given in Table 1. 
 
Figure 1: Suggested pharmacophore model for 
semicarbazones displaying anticonvulsant ac-
tivity 
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Table 1: Physico-chemical parameters data of the newly synthesized derivatives 
 
Figure 2: Structure of proposed general phar-
macophore model of the synthesized compound 
and reported chemical drugs 
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PHARMACOLOGY 
Anticonvulsant screening 
The anticonvulsant evaluation of the 
synthesized compounds was performed us-
ing reported procedure (Krall et al., 1978). 
Male albino mice (CF-1 strain, 18 – 25 g) 
were used as experimental animal. The syn-
thesized compounds were suspended in 
polyethylene glycol (PEG- 400). All exper-
imental protocols were carried out with 
permission from the Institutional Animal 
Ethics Committee (IAEC). Animals were 
obtained from the Central Animal House 
Facility, DR. K. N. Modi Institute of Phar-
maceutical Education and Research, 
Modinagar, Ghaziabad, Uttar Pradesh, In-
dia. 
 
Electroshock seizure method  
Initial anticonvulsant evaluation of test 
compounds DH-01–DH-14 were under tak-
en by maximal electroshock seizure (MES) 
test following the method of Krall et al. 
(1978). Maximal seizures were induced by 
the application of electrical current to the 
brain via corneal electrodes. For all tests 
based on MES convulsions, 60 Hz of alter-
nating current (50 mA) was delivered for 
0.2 s by corneal electrodes which had been 
primed with an electrolyte solution contain-
ing an anaesthetic agent (0.5 % tetracaine 
HCl). Abolition of the hind limb tonic ex-
tensor spasm was recorded as a measure-
ment of anticonvulsant activity. 
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Rotarod motor impairment screening 
Motor impairment is measured in mice 
by the rotarod test (Dunham et al., 1957). 
The mice were trained to stay on an accel-
erating rotarod (INCO, Ambala, India) that 
rotated at six revolutions per minute. The 
rod diameter was 3.2 cm. Motor impair-
ment was indicated by the inability of the 
animal to maintain equilibrium on the rod 
for at least 1 min in each of the trials. 
 
CNS depression study 
The forced swim method (Porsolt’s 
swim pool test) (Porsolt et al., 1978) was 
followed to study the CNS depression. 
Mice were placed in a chamber (diameter 
45 cm, height 20 cm) containing water up 
to a height of 15 cm at 25 ± 2 °C. Two 
swim sessions were conducted, an initial 
15 min pre-test, followed by a 5 min test 
session 24 h later. The animals were admin-
istered an i.p. injection (100 mg/kg) of the 
test compounds 30 min before the test ses-
sion. The period of immobility (passive 
floating without struggling, making only 
those movements which are necessary to 
keep its head above the surface of water) 
during the 5 min test period were measured. 
 
COMPUTATIONAL STUDY  
Calculation of physicochemical  
parameters 
A computational study of synthesized 
compounds (DH-01–DH-14) was per-
formed for prediction of ADME properties. 
Polar surface area (TPSA) (Ertl et al., 
2000), number of rotatable bonds, molecu-
lar volume, number of hydrogen donor and 
acceptor atoms and violations of Lipinski’s 
rule of five (Lipinski et al., 2001) were cal-
culated using Molinspiration online proper-
ty calculation toolkit (Molinspiration 
Cheminformatics, 2013). Absorption 
(%ABS) was calculated by: %ABS=109 -
 (0.345 × TPSA) (Zhao et al., 2002). The 
theoretical toxicity, druglikeness and drug-
score properties were calculated in the Osi-
ris Property Explorer (http://www.organic-
chemistry. org). 
RESULTS AND DISCUSSION  
Anticonvulsant and CNS depressant  
activities 
Synthesized 5,7-dibromoisatin semi-
carbazone derivatives were screened for 
their anticonvulsant activity by using stand-
ard model MES (maximal electroshock sei-
zure test) for their ability to reduce seizure 
spread (Table 2). Motor impairment screen-
ing of the synthesized compounds was also 
carried out by rotarod test method and CNS 
depressant effect of the compounds was de-
termined by porsolt’s force swim pool 
method. The anticonvulsant activity was 
tested after 0.5 and 4.0 h time intervals at 
dose levels of 30, 100, 300 mg/kg body 
weight. The CNS depressant activity was 
studied at a dose level of 100 mg/kg body 
weight. Phenytoin and Carbamazepine were 
used as standard drugs. 
In this series (DH-01–DH-14), com-
pounds DH-03, DH-06 and DH-08 showed 
protection against induced seizures at max-
imum dose (300 mg/kg) after 4.0 h. Com-
pound DH-05 showed protection at a dose 
of 100 mg/kg at 4.0 h and compounds DH-
11 and DH-12 showed the activity at the 
dose of 30 mg/kg at 0.5 h. The compounds 
DH-02, and DH-04 showed protection at a 
dose of 100 mg/kg at 4.0 h and compound 
DH-09 showed protection at a dose of 
100 mg/kg at 0.5 h. Compounds DH-11 and 
DH-12 having R1 = Flouro, R2 = Chloro, 
R4 = H, and R1 = Flouro, R2 = Chloro, 
R4= CH3 groups respectively were found 
most active in the series showing activity at 
0.5 h at lower dose of 30 mg/kg. In the 
rotarod motor impairment screening, all 
compounds except DH-03, DH-05, DH-06 
and DH-08, showed motor impairment at 
the maximum dose of 300 mg/kg. 
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Table 2: Anticonvulsant and motor impairment 
screening of synthesized compounds (DH-01-
DH-14) using maximal electroshock seizure 
(MES) Model and Rotarod Model 
Compound 
Code 
MESa Motor Impt.a 
0.5h 4.0h 0.5 h 4.0 h 
DH-01 - - - 300 
DH-02 - 100 - 300 
DH-03 - 300 - - 
DH-04 - 100 - 300 
DH-05  100 - - 
DH-06  300 - - 
DH-07 - - - 300 
DH-08 - 300 - - 
DH-09 100 - - 300 
DH-10 - - 100 - 
DH-11 - 30 300 - 
DH-12 - 30 300 - 
DH-13 - 100 - 100 
DH-14 - 100 - 100 
Control - - - - 
Phenytoin 30 30 100 100 
Carbama-
zepine 30 100 300 - 
aDoses of 30, 100, and 300 mg/kg were administered to 
mice through intraperitoneal route. The figures in the table 
indicate the minimum dose whereby bioactivity was demon-
strated in half or more of mice. The animals were examined 
0.5 and 4h after the drug administration. The dash (-) indi-
cates an absence of activity at maximum dose administered 
(300 mg/kg). Data for Phenytoin and Carbamazepine, used 
as standard drugs, were obtained referring, Dimmock, J.R., 
et al 1995 & White, H.S., et al 1995. 
 
Some selected compounds i.e. DH-05, 
DH-11 and DH-12 having significant anti-
convulsant activity were also tested for 
their CNS depressant effect. These com-
pounds with respect to control, showed 
29.05, 51.24 and 32.95 % increase in im-
mobility time respectively. The standard 
drug carbamazepine showed 58.63 % in-
crease in the immobility time (Table 3). 
Percentage CNS depression by DH-11 was 
in the vicinity of carbamazepine while DH-
05 and DH-11 fell far behind.  
DH-05, with p-chloro in its structure 
was found to be the most active compound 
of this study. It was effective in 4.0 h time 
interval against induced seizure at lower 
dose of 100 mg/kg, showing no motor im-
pairment effect in comparison to standard 
drug Carbamazepine. The activity may be 
due to the presence of chlorine at para posi-
tion which is well fitted to receptor site 
though, it showed reduced CNS depressant 
effect in comparison to standard drug, car-
bamazepine.  
Using the putative binding site theory 
proposed by Dimmock et al. (2000a, b) 
subsequently used by others (Pandeya et al., 
2002; Gibson et al., 2009) in postulating the 
interaction of anticonvulsant compounds at 
a specific binding site, the molecule ob-
served to interact with the protein receptor 
as shown in Figure 3. 
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Figure 3: Proposed binding interactions of the 
title compounds using putative binding site the-
ory (Dimmock et al., 2000a, b; Pandeya et al., 
2002; Gibson et al., 2009). 
 
 
 
Table 3: Data of CNS depressant activity of the 
selected compounds performed in mice using 
forced swim test 
Com-
pounds 
Duration of  
immobility 
(sec)  
(mean ± SEM) 
% In-
creased 
of immobil-
ity 
DH-05 68.45 ± 5.28 29.05 
DH-11 80.22 ± 2.66 51.24 
DH-12 70.52 ± 2.45 32.95 
Carbama- 
zepine 84.14 ± 1.33 58.63 
Control 53.04 ± 2.47 - 
Tested at 100 mg/kg (i.p. in PEG 400); control animals were 
administered PEG 400 (i.p.). Each value represents the 
mean ± SEM of six mice. The CNS depressant effect was 
compared with respect to standard drug. *p < 0.0001. Data 
was analyzed by unpaired student’s t test. 
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Prediction of ADME properties 
A computational study for prediction of 
ADME properties of synthesized com-
pounds was performed. Topological polar 
surface area (TPSA), i.e., surface belonging 
to polar atoms, is a descriptor that was 
shown to correlate well with passive mo-
lecular transport through membranes and, 
therefore, allows prediction of transport 
properties of drugs in the intestines and 
blood-brain barrier crossing (Ertl et al., 
2000). The percentage of absorption 
(%ABS) was calculated using TPSA. From 
all these parameters, it can be observed that 
all synthesized compounds exhibited a great 
%ABS ranging from 74.38 to 82.955 % 
(Table 4). Furthermore, compounds DH-01, 
DH-07 and DH-08, DH-12 violated only 
one and two Lipinski’s parameter respec-
tively. None of the other compounds violat-
ed Lipinski’s parameters, making them po-
tentially promising agents for epilepsy ther-
apy. Although druglikeness of DH-11 and 
DH-12 was not comparable to standard 
drug but DH-05 was shown more 
druglikeness when compared to the 
standard drug. Drug scores of DH-11 and 
DH-12 were low, but for DH-05, it lies in 
the close proximity with phenatoin. Using 
orisis programe, theoretical toxicity profile 
(Mutagenic, tumorigenic, irritant and 
reproductive effective) of the all three 
compounds DH-05, DH-11 and DH-12 
were analysed and found to be equal to that 
of the standard drug Phenatoin (Figure 4). 
 
CONCLUSION 
In conclusion, the present study indicat-
ed that the synthesized compounds have 
marked anticonvulsant activity as indicated 
by the protection against maximal electro-
shock induced seizures in comparison with 
standard drug (Phenytoin) with little or no 
neurotoxicity. Further, the study highlights 
the importance of the structural features of 
a compound responsible for the anticonvul-
sant activity. With semicarbazone structure 
as a template, many modifications can still 
be carried out and there is ample scope for 
further exploration which will lead to a sys-
tematic structure-activity relationship. 
 
 
 
 
 
Figure 4: Graphical representation of Druglikeness and drugscore values of compounds DH-05,  
DH-11, DH-12 and Phenytoin 
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Table 4: Pharmacokinetic parameters important for good oral bioavailability of compounds. 
Com-
pound  % ABS 
TPSA 
(A2) 
n-
ROTB MW MV 
n-OHNH 
donors 
n-ON 
acceptors 
Lipinski’s 
violations 
Rule - - - <500 - <5 <10 <1 
DH-1 74.380 100.347 1 361.981 206.293 4 6 1 
DH-2 78.125 89.49 1 376.008 223.236 3 6 0 
DH-3 79.209 86.351 2 438.079 278.816 3 6 0 
DH-4 82.955 75.494 2 452.106 295.758 2 6 0 
DH-5 79.209 86.351 2 472.524 292.352 3 6 0 
DH-6 82.955 75.494 2 486.551 309.294 2 6 0 
DH-7 79.209 86.351 2 516.975 296.701 3 6 1 
DH-8 82.955 75.494 2 531.002 313.644 2 6 2 
DH-9 79.209 86.351 2 472.524 292.352 3 6 0 
DH-10 82.955 75.494 2 486.551 309.294 2 6 0 
DH-11 79.209 86.351 2 490.514 297.283 3 6 0 
DH-12 82.955 75.494 2 504.541 314.22 2 6 2 
DH-13 79.209 86.351 2 452.106 295.377 3 6 0 
DH-14 82.955 75.494 2 466.133 312.319 2 6 0 
%ABS, percentage of absorption; TPSA, topological polar surface area; n-ROTB, number of rotatable bonds; MW, molecular 
weight; MV, molecular volume; n-OHNH, number of hydrogen bond donors; n-ON, number of hydrogen bond acceptors 
 
 
EXPERIMENTAL PROTOCOL 
Chemistry 
Raw materials for the synthesis were 
purchased from Merck (India), Spectro-
chem chemicals (India) and S.D. Fine Che-
micals (India). The progress of reaction was 
monitored by thin layer chromatography, 
performed on Silica gel-GF coated alumi-
num plate using iodine vapors and UV light 
as visualizing agents. Evaporation of sol-
vents was performed at reduced pressure, 
using a Buchi rotary evaporator. Solid pro-
ducts were purified by recrystallization and 
column chromatography. Melting points of 
newly synthesized compounds were deter-
mined in open glass capillary with the help 
of digital melting point apparatus and are 
uncorrected. FT-IR (KBr) spectra were rec-
orded on a Nicolet 5PC FTIR spectropho-
tometer (λ-max in cm-1). 1H NMR spectra 
was recorded on a Brucker Model-300 
NMR Spectrometer in DMSO-d6 using tet-
ramethylsilane (TMS) as the internal refer-
ence (chemical shifts in δ ppm). Chemical 
shifts are reported in ppm downfield from 
tetramethylsilane (TMS). 
Synthesis of 5,7-dibromoisatin 
The synthesis of 5,7-Dibromoisatin was 
based on the method of Lindwall. Isatin 
(5.0 g, 34 mmol, 1 equiv) was warmed in 
ethanol (95 %, 100 mL) with stirring until it 
dissolved. Bromine (16.3 g, 102 mmol, 
5.2 mL, 3.0 equiv) was added dropwise to 
the stirred isatin solution whilst maintaining 
the temperature of the reaction mixture be-
tween 70 to 75 °C. The solution was cooled 
to room temperature and placed on ice for 
30 min. The resulting precipitate was 
washed with water and cold ethanol and 
then recrystallized from ethanol to yield 
bright orange-red crystals of 5,7-dibro-
moisatin (60 %), m.p. 251–254 °C (Vine et 
al., 2007, 248–250 °C). 
 
Synthesis of N-methyl 5,7-dibromoisatin 
To a suspension of (0.1 mol) of dibromo 
isatin, in 200 ml of anhydrous methanol, 
100 mL of 10 % methanolic potassium hy-
droxide solution was added in portions with 
stirring for 30 min. To this mixture, 15 mL 
of dimethyl sulfate was added and after 1 h, 
the solution was filtered to remove potassi-
um methyl sulfate. After removal of about 
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250 mL of solvent under reduced pressure, 
40 mL of warm water was added to the ob-
tained residue. On cooling, orange precipi-
tate occurred which was filtered and dried 
to obtain N-Methyl 5,7-Dibromoisatin 
(Gupta et al., 2010). 
 
Synthesis of substituted aryl  
semicarbazides  
Substituted aryl ureas were prepared ac-
cording to the prescribed procedure (Fur-
niss et al., 1998). The substituted phenyl 
semicarbazides (H, 2-Cl, 4-Cl, 4-Br, and 4-
CH3 etc.) were synthesized according to 
earlier reported methods. 
Phenyl semicarbazide (Pandeya et al., 
1999) 
Yield: 62 % m. p. 245°C. (lit. 247°C); 
N-(2-Chlorophenyl)hydrazinecarboxamide 
(o-Chlorophenyl semicarbazide) (Pan-
deya et al., 1999) 
Yield : 65 %, m. p. 176°C (lit. 179°C); 
N-(4-Chlorophenyl)hydrazinecarboxamide 
(p-Chlorophenyl semicarbazide) (Pan-
deya et al., 1999) 
Yield : 70 %, m. p. 235°C (lit. 234°C); 
N-(4-Bromophenyl)hydrazinecarboxamide 
(p-Bromophenyl semicarbazide) (Pan-
deya et al., 2000) 
Yield: 40 %, m. p. 267°C (lit. 270°C); 
3-Chloro-4-Flourophenyl semicarbazide 
(Amir et al., 2010) 
Yield: 60 %, m. p. 94°C (lit. m.p 90-920C.) 
4-p-tolylsemicarbazide (p-Methylphenyl 
semicarbazide) (Wheeler et al., 1924,) 
Yield: 61 %, m. p. decomposing at 272°C 
(lit. m.p decomposing at 2740C.) 
 
General procedure for synthesis of substi-
tuted dibromoisatin semicarbazones 
Dibromoisatin semicarbazones DH-01 
to DH-14 were synthesized according to the 
procedure specified in literature with some 
modifications (Amir et al., 2010) as shown 
in synthetic Scheme 1. To a solution of sub-
stituted semicarbazide (0.0025 mole) in 0.5 
mL conc. HCl and 12.5 mL water, sodium 
acetate (0.0025 mole, 0.205g) in 1 mL wa-
ter was added. About 12.5 mL ethanol was 
added to clear the turbidity. This solution 
mixture was added to an equimolar quantity 
of the appropriate dibromoisatin or N-
methyl dibromoisatin in alcohol. The solu-
tion was stirred for 15 min. precipitation 
occurred immediately (if immediate precip-
itation did not occur, reaction mixture 
would be allowed to stand for 1-2 h), and 
the solids were filtered, dried and purified 
by recrystallization from ethanol. The ho-
mogeneity of the compounds was checked 
by TLC using n-Hexane + ethyl acetate 
(1:1) as mobile phase. 
 
(Z)-1-(5,7-dibromo-2-oxoindolin-3-
ylidene)semicarbazide DH-01 
IR (KBr): max = 3267 (NH), 1720 (C=O), 
1610 (C=N), 1021 (C-Br) cm-1. 1H NMR 
(300 MHZ, DMSO-d6)  = 7.33 (brs, 2 H, 
CONH2), 7.62-7.85 (m, 2H, ArH), 11.56 
(s, 1 H, =N-NH), 11.62 (s, 1 H, NH), 
ppm. Anal. calcd for C9H6Br2N4O2 
(359.8858): C 29.88, H 1.86, N 15.62; 
found C 29.94, H 1.70, N 15.70. 
 
(Z)-1-(5,7-dibromo-1-methyl-2-
oxoindolin-3-ylidene)semicarbazide 
DH-02 
IR (KBr): max = 3251 (NH), 1725 (C=O), 
1598 (C=N), 1025 (C-Br) cm-1. 1H NMR 
(300 MHZ, DMSO-d6)  = 2.50 (s, 3 H, 
N- CH3), 7.33 (brs, 2 H, CONH2), 7.62-
7.85 (m, 2H, ArH), 11.56 (s, 1 H, =N-
NH), ppm. Anal. calcd for 
C10H8Br2N4O2 (373.9014): C 31.90, H 
2.10, N 14.86; found C 31.98, H 1.99, N 
14.98. 
 
(Z)-1-(5,7-dibromo-2-oxoindolin-3-
ylidene)-4-phenylsemicarbazide DH-03 
IR (KBr): max = 3415 (NH), 1730 (C=O), 
1670 (C=O amide), 1601 (C=N), 1015 
(C-Br) cm-1. 1H NMR (300 MHZ, 
DMSO-d6)  = 7.25-7.53 (m, 5 H, ArH), 
7.73-7.84 (m, 2 H, ArH), 9.72 (brs, 1 H, 
ArNH), 11.65 (brs, 1 H, NH), 12.10 (s, 1 
H, CONH) ppm. Anal. calcd for 
C15H10Br2N4O2 (435.9171): C 41.10, H 
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2.20, N 12.70; found C 41.20, H 2.05, N 
12.75. 
 
(Z)-1-(5,7-dibromo-1-methyl-2-
oxoindolin-3-ylidene)-4-
phenylsemicarbazide DH-04 
IR (KBr): max = 3410 (NH), 1732 (C=O), 
1675 (C=O amide), 1601 (C=N), 1012 
(C-Br) cm-1. 
1H NMR (300 MHZ, DMSO-d6)  = 2.58 
(s, 3 H, N- CH3), 7.23-7.63 (m, 5 H, 
ArH), 7.72-7.81 (m, 2 H, ArH), 9.78 
(brs, 1 H, ArNH), 12.10 (s, 1 H, CONH) 
ppm. Anal. calcd for C16H12Br2N4O2 
(452.1001): C 42.45, H 2.60, N 12.38; 
found C 42.48, H 2.55, N 12.42. 
 
(Z)-1-(5,7-dibromo-2-oxoindolin-3-
ylidene)-4-(4-
chlorophenyl)semicarbazide DH-05 
IR (KBr): max = 3424 (NH), 1738 (C=O), 
1657 (C=O amide), 1607 (C=N), 1018 
(C-Br) cm-1. 
1H NMR (300 MHZ, DMSO-d6)  = 7.15 
(d, J = 8.1 Hz, 2 H, ArH), 7.75 (d, J = 
8.1 Hz, 2 H, ArH), 7.76-7.78 (m, 2 H, 
ArH), 9.76 (brs, 1 H, ArNH), 11.62 (brs, 
1 H, NH), 12.03 (s, 1 H, CONH) ppm. 
Anal. calcd for C15H9Br2ClN4O2 
(469.8781): C 38.16, H 1.90, N 11.80; 
found C 31.20, H 1.88, N 11.84. 
 
(Z)-1-(5,7-dibromo-1-methyl-2-
oxoindolin-3-ylidene)-4-(4-
chlorophenyl)semicarbazide DH-06 
IR (KBr): max = 3343 (NH), 1730 (C=O), 
1657 (C=O amide), 1610 (C=N), 1012 
(C-Br) cm-1. 1H NMR (300 MHZ, 
DMSO-d6)  = 2.51 (s, 3 H, N- CH3), 
7.40 (d, J = 6.9 Hz, 2 H, ArH), 7.80 (d, J 
= 14.1 Hz, 2 H, ArH), 8.06-8.40 (m, 2 H, 
ArH), 9.75 (brs, 1 H, ArNH), 11.25 (s, 1 
H, CONH) ppm. Anal. calcd for 
C16H11Br2ClN4O2 (483.8937): C 39.45, 
H 2.18, N 11.50; found C 39.55, H 2.30, 
N 11.48. 
 
(Z)-1-(5,7-dibromo-2-oxoindolin-3-
ylidene)-4-(4-bromophenyl) semicarba-
zide DH-07 
IR (KBr): max = 3324 (NH), 1740 (C=O), 
1648 (C=O amide), 1601 (C=N), 1019 
(C-Br) cm-1. 
1H NMR (300 MHZ, DMSO-d6)  = 7.25 
(d, J = 8.3 Hz, 2 H, ArH), 7.78 (d, J = 
8.5 Hz, 2 H, ArH), 7.66-7.79 (m, 2 H, 
ArH), 9.72 (brs, 1 H, ArNH), 11.70 (brs, 
1 H, NH), 12.10 (s, 1 H, CONH) ppm. 
Anal. calcd for C15H9Br3N4O2 
(513.8276): C 34.80, H 1.70, N 10.80; 
found C 34.88, H 1.80, N 10.85. 
 
(Z)-1-(5,7-dibromo-1-methyl-2-
oxoindolin-3-ylidene)-4-(4-
bromophenyl)semicarbazide DH-08 
IR (KBr): max = 3340 (NH), 1730 (C=O), 
1652 (C=O amide), 1609 (C=N), 1017 
(C-Br) cm-1. 1H NMR (300 MHZ, 
DMSO-d6)  = 2.56 (s, 3 H, N- CH3), 
7.50 (d, J = 6.7 Hz, 2 H, ArH), 7.86 (d, J 
= 14.5 Hz, 2 H, ArH), 8.09-8.42 (m, 2 H, 
ArH), 9.72 (brs, 1 H, ArNH), 11.65 (s, 1 
H, CONH) ppm. Anal. calcd for 
C16H11Br3N4O2 (527.8432): C 36.15, H 
2.10, N 10.55; found C 36.20, H 2.05, N 
10.60. 
 
(Z)-1-(5,7-dibromo-2-oxoindolin-3-
ylidene)-4-(2-
chlorophenyl)semicarbazide DH-09 
IR (KBr): max = 3438 (NH), 1739 (C=O), 
1611 (C=N), 1022 (C-Br) cm-1. 1H NMR 
(300 MHZ, DMSO-d6)  = 7.51-7.63 (m, 
4 H, ArH), 7.87 (m, 2H, ArH), 9.96 (s, 1 
H, ArNH), 11.63 (brs, 1H, NH), 12.09 
(s, 1 H, CONH). ppm. Anal. calcd for 
C15H9Br2ClN4O2 (469.8781): C 38.10, H 
1.90, N 11.80; found C 38.15, H 1.88, N 
11.84. 
 
(Z)-1-(5,7-dibromo-1-methyl-2-
oxoindolin-3-ylidene)-4-(2-
chlorophenyl)semicarbazide DH-10 
IR (KBr): max = 3416 (NH), 1729 (C=O), 
1601 (C=N), 1021 (C-Br) cm-1. 1H NMR 
(300 MHZ, DMSO-d6)  = 2.48 (s, 3 H, 
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N- CH3), 7.31-7.53 (m, 4 H, ArH), 7.76 
(m, 2H, ArH), 9.92 (s, 1 H, ArNH), 
12.19 (s, 1 H, CONH.) ppm. Anal. calcd 
for C16H11Br2ClN4O2 (483.8937): C 
39.45, H 2.20, N 11.45; found C 39.48, 
H 2.18, N 11.42. 
 
(Z)-1-(5,7-dibromo-2-oxoindolin-3-
ylidene)-4-(3-chloro-4-
fluorophenyl)semicarbazide DH-11 
IR (KBr): max = 3235 (NH), 1728 (C=O), 
1607 (C=N), 1021 (C-Br) cm-1. 1H NMR 
(300 MHZ, DMSO-d6)  = 2.51 (s, 3 H, 
N- CH3), 7.27-7.45 (m, 3 H, ArH), 7.86 
(m, 2 H, ArH), 9.99 (brs, 1 H, ArNH), 
12.06 (s, 1 H, CONH) ppm. Anal. calcd 
for C15H8Br2ClFN4O2 (487.8687): C 
36.70, H 1.60, N 11.40; found C 36.80, 
H 1.55, N 11.45. 
 
(Z)-1-(5,7-dibromo-1-methyl-2-
oxoindolin-3-ylidene)-4-(3-chloro-4-
fluorophenyl)semicarbazide DH-12 
IR (KBr): max = 3233 (NH), 1727 (C=O), 
1604 (C=N), 1019 (C-Br) cm-1. 1H NMR 
(300 MHZ, DMSO-d6)  = 2.49 (s, 3 H, 
N- CH3), 7.25-7.46 (m, 3 H, ArH), 7.82 
(m, 2 H, ArH), 9.95 (brs, 1 H, ArNH), 
12.11 (s, 1 H, CONH) ppm. Anal. calcd 
for C16H10Br2ClFN4O2 (501.8843): C 
38.10, H 1.98, N 11.02; found C 38.15, 
H 1.92, N 11.08. 
 
(Z)-1-(5,7-dibromo-2-oxoindolin-3-
ylidene)-4-p-tolylsemicarbazide DH-13 
IR (KBr): max = 3336 (NH), 1734 (C=O), 
1654 (C=O amide), 1598 (C=N), 1013 
(C-Br) cm-1. 
1H NMR (300 MHZ, DMSO-d6)  = 2.74 
(s, 3 H, ArCH3), 7.23 (d, J = 7.4 Hz, 2 
H, ArH), 7.65 (d, J = 6.4 Hz, 2 H, ArH), 
7.73-7.75 (m, 2 H, ArH), 9.85 (brs, 1 H, 
ArNH), 11.58 (brs, 1 H, NH), 12.14 (s, 1 
H, CONH) ppm. Anal. calcd for 
C16H12Br2N4O2 (449.9327): C 42.45, H 
2.60, N 12.30; found C 42.48, H 2.58, N 
12.35. 
 
(Z)-1-(5,7-dibromo-1-methyl-2-
oxoindolin-3-ylidene)-4-p-
tolylsemicarbazide DH-14 
IR (KBr): max = 3315 (NH), 1737 (C=O), 
1656 (C=O amide), 1602 (C=N), 1021 
(C-Br) cm-1. 1H NMR (300 MHZ, 
DMSO-d6)  = 2.53 (s, 3 H, N- CH3), 
2.70 (s, 3 H, ArCH3), 7.45 (d, J = 7.1 
Hz, 2 H, ArH), 7.68 (d, J = 6.1 Hz, 2 H, 
ArH), 7.72-7.76 (m, 2 H, ArH), 9.72 
(brs, 1 H, ArNH), 12.08 (s, 1 H, CONH) 
ppm. Anal. calcd for C17H14Br2N4O2 
(463.9484): C 43.75, H 3.00, N 12.00; 
found C 43.80, H 2.98, N 12.21. 
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